Drugs / RAPIROSIRAN
RAPIROSIRAN
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04565717 | Oct 2020 → Jan 2023 | metabolic dysfunction-associated steatohepatitis | Alnylam Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
| Phase 21 trial | ||||||
| Phase 2 | NCT05519475 | Feb 2023 → Apr 2028 expected | metabolic dysfunction-associated steatohepatitis | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2023-08-03 | Alnylam Pharmaceuticals | Results Alnylam Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Period Activity alnylam.com ↗
Presented findings from a Phase 1 study of ALN-HSD in healthy adults and patients with nonalcoholic steatohepatitis at the European Association for the Study of the Liver (EASL) Congress 2023. |
| 2022-09-15 | Alnylam Pharmaceuticals | Results Alnylam and Regeneron Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers alnylam.com ↗ |
| 2022-09-15 | Regeneron Pharmaceuticals | Results Regeneron and Alnylam Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers regeneron.com ↗
Regeneron Pharmaceuticals (Nasdaq: REGN) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today preliminary Phase 1 data supporting the clinical advancement of ALN-HSD, an investigational RNAi therapeutic targeting HSD17B13 in development for the treatment of nonalcoholic steatohepatitis (NASH). |
| 2020-08-03 | Alnylam Pharmaceuticals | Regulatory Alnylam Submits CTA Application for ALN-HSD, an Investigational RNAi Therapeutic for the Treatment of Nonalcoholic Steatohepatitis (NASH) alnylam.com ↗ |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-08-03 | Alnylam Pharmaceuticals | Alnylam Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Period Activity alnylam.com ↗ |
| 2022-09-15 | Alnylam Pharmaceuticals | Alnylam and Regeneron Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers alnylam.com ↗ |
| 2022-09-15 | Regeneron Pharmaceuticals | Regeneron and Alnylam Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers regeneron.com ↗ |
| 2020-08-03 | Alnylam Pharmaceuticals | Alnylam Submits CTA Application for ALN-HSD, an Investigational RNAi Therapeutic for the Treatment of Nonalcoholic Steatohepatitis (NASH) alnylam.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RAPIROSIRAN | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314632 ↗ |
| Known as | AD-288996 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314632 ↗ |
| Known as | ALN-288996 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314632 ↗ |
| Known as | ALN-HSD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05519475 ↗ |
| Modality | Small interfering RNA (siRNA) | “siRNA Gene Silencing” NCT05519475 ↗ |
| Route | Subcutaneous | “ALN-HSD will be administered by subcutaneous (SC) injection.” NCT04565717 ↗ |